Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
ReNeuroGen
AddedFeb 17, 2024
UpdatedJul 17, 2026
ReNeuroGen

ReNeuroGen

Angel

ReNeuroGen: A virtual pharma company innovating therapies for neurological and pulmonary diseases.

HQ
Elm Grove, WI, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

ReNeuroGen, founded with a mission to innovate in the pharmaceutical field, focuses on developing systems pharmacology therapies targeting neurological and pulmonary diseases. As a virtual pharmaceutical company, ReNeuroGen leverages cutting-edge chemico-pharmacology to create first-in-class agents that address multi-target disease states. Their lead candidate, KYC, is a tripeptide myeloperoxidase inhibitor designed to reduce inflammation and mitigate disease symptoms effectively.

Notable figures associated with ReNeuroGen include experts in pharmacology and neurology, though specific names are not provided. The company has achieved significant milestones in the development of their lead candidate, KYC, which shows promise in treating complex inflammatory conditions. ReNeuroGen's innovative approach has the potential to make a substantial impact on the treatment landscape for neurological and pulmonary diseases, offering new hope for patients with these challenging conditions.

ReNeuroGen - Similar Companies

Neurogene logo

Neurogene

neurogene.com

Neuraly logo

Neuraly

neuralymed.com

NeuroTherapeutics Pharma logo

NeuroTherapeutics Pharma

Regennova logo

Regennova

regennova.com

Neurodon logo

Neurodon

neurodon.net

NeuroGenetic Pharmaceuticals logo

NeuroGenetic Pharmaceuticals

NeuroTherapia logo

NeuroTherapia

neurotherapia.com

NeuroCytonix logo

NeuroCytonix

neurocytonix.com

Neurovia logo

Neurovia

Neurana Pharmaceuticals logo

Neurana Pharmaceuticals

neuranapharma.com

NeuroPro Therapeutics logo

NeuroPro Therapeutics

Neuroene Therapeutics logo

Neuroene Therapeutics

NeuroX1 logo

NeuroX1

neurox1.com

Empyrean Neuroscience logo

Empyrean Neuroscience

empyrean.bio

Neuron23 logo

Neuron23

ReNeuroGen - Quick Facts

Who are ReNeuroGen's competitors?

Companies similar to ReNeuroGen include Neurogene, Neuraly, NeuroTherapeutics Pharma and Regennova.

When was ReNeuroGen founded?

ReNeuroGen was founded in 2016.

Where is ReNeuroGen's headquarters located?

ReNeuroGen's headquarters is located in Elm Grove, WI, US.

When was ReNeuroGen's last funding round?

ReNeuroGen's most recent funding round was for $75k (USD) in January 2022.

How much has ReNeuroGen raised to-date?

As of Jan 10, 2022, ReNeuroGen has raised a total of $75k (USD).

How many employees does ReNeuroGen have?

ReNeuroGen has 3 employees as of Feb 4, 2024.

ReNeuroGen - Classification

Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified